Stock Movers Amazon Falls, Honeywell Rises, Hims & Hers Health Surges on Wegovy Deal
Apr 29, 2025
Amazon faces stock turmoil after a government critique over tariff transparency, leading to a sharp decline. In contrast, Honeywell's shares soar as it raises its earnings forecast and outlines strategies to mitigate tariff impacts through a planned split into three firms. Meanwhile, Hims & Hers Health celebrates a remarkable stock surge thanks to a new partnership that offers the popular weight-loss drug Wegovy at a competitive price through telehealth platforms. This dynamic interplay illustrates the ever-changing stock market landscape.
AI Snips
Chapters
Transcript
Episode notes
Amazon's Tariff Transparency Controversy
- Amazon plans to show tariff costs as a separate part of product prices on its website.
- The White House sees this transparency move as a politically hostile act by Amazon.
Honeywell Overcomes Tariff Challenges
- Honeywell raised its earnings forecast despite facing $500 million in tariff costs.
- The company plans to mitigate tariffs through price adjustments and splitting into three companies.
Hims & Hers Boosted by Wegovy Deal
- Hims & Hers stock surged 33% after announcing a deal to sell Wegovy at a reduced price.
- The drug will be offered on telehealth platforms starting at $499 per month through NovoCare.